OVERVIEW

Quality Bone Densitometry: Performance, Interpretation, and Clinical Application for Clinicians is organized by International Society for Clinical Densitometry (ISCD) and will be held from Feb 27 - 28, 2021.

Accreditation Statement:
The International Society for Clinical Densitometry is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

AMA PRA Category 1 Credit(s)
The International Society for Clinical Densitometry designates this live educational activity for a maximum of 11.5 AMA PRA Category 1 Credits. Physicians should only claim credits commensurate with the extent of their participation in the activity.

Course Overview:
Quality Bone Densitometry: Performance, Interpretation, and Clinical Application for Clinicians

An Osteoporosis Essentials Course of the International Society for Clinical Densitometry & International Osteoporosis Foundation
The core elements of this course serve to increase the knowledge and competence of clinicians regarding bone densitometry and osteoporosis diagnosis, clinical evaluation, treatment, and monitoring and to apply standard practices to assure quality performance and interpretation of bone densitometry studies. The first day sets the standard to perform quality DXA interpretation, while the second day focuses on the clinical assessment, prevention, treatment, and management/monitoring of osteoporosis and the essential role that high-quality DXA plays in treatment initiation decisions and monitoring of osteoporotic patients.

Overall Course Objectives:
After attending the course, participants should be better prepared to:
• Describe the appropriate clinical evaluation of patients at risk for fragility fracture.
• Summarize the value and importance of quality bone densitometry for the diagnosis of osteoporosis, assessment of fracture risk, and monitoring of BMD.
• Recognize errors in DXA analysis and reporting.
• Explain new and emerging guidelines that provide evidence-based information regarding skeletal health.
• Describe the use of current and new pharmacologic therapies for the management and treatment of osteoporosis, including adverse effects.